1.14.14.32	drug development	regioisomeric 17beta-N-phenylpyrazolyl steroid derivatives have weak inhibitory effect on 17alpha-hydroxylase/C17,20-lyase	706778	
1.14.14.32	drug development	silencing CYP17 expression may be a strategy for therapy of hyperandrogenism diseases, and also sets an example for the use of RNAi technology in endocrine diseases	706689	
1.14.14.32	medicine	combined 17alpha-hydroxyprogesterone aldolase/17,20-lyase deficiency is a rare, autosomal recessive form of congenital adrenal hyperplasia	690654	
1.14.14.32	medicine	homology modelling of the enzyme cytochrome P450 17alpha-hydroxylase/17,20-lyase (P450c17)-a target for prostate cancer chemotherapy-from the crystal structure of P450BM-3	5131	
1.14.14.32	medicine	inhibition of 17alpha-hydroxylase-C(17,20)-lyase can block androgen synthesis at an early stage, and may therefore be useful in the treatment of prostatic carcinoma	695147	
1.14.14.32	medicine	inhibition of EC 4.1.2.30 is a potential therapeutic approach for the treatment of both breast and prostrate cancers	5130	
1.14.14.32	medicine	inhibitor VT-464 displays selective suppression of androgen synthesis through CYP17 lyase inhibition. VT-464 shows a greater decrease in androgen receptor transactivation than inhibitor abiraterone	745754	
1.14.14.32	medicine	inhibitors of 17alpha-hydroxylase/17,20 lyase are a class of anti-prostate cancer agents	694115	
1.14.14.32	medicine	inhibitors of 17alpha-hydroxylase/17,20 lyase are a new class of anti-prostate cancer agents	694117	
1.14.14.32	medicine	partial 17alpha-hydroxylase/17,20-lyase deficiency is a very rare form of congenital adrenal hyperplasia	693809